The Craving Doesn't Expire on Your Sobriety Anniversary
New brain-imaging and animal research show why urges to use heroin can persist for years after the drug is gone from your system — and why treatment built around a fixed calendar undersells the disorder.
Heroin is quietly disappearing from the nation’s death certificates. The CDC’s latest overdose data brief puts the heroin-involved death rate at 0.8 per 100,000 people in 2024, down a third from 1.2 the year before, part of an overall 26 percent drop in overdose deaths as the drug supply shifts toward fentanyl. That’s real progress in a body count. It says nothing about what’s happening inside the people who used heroin and are still, years later, fighting the pull of it.
The craving does not run out on a schedule, and treatment built around 28 days or 90 days is sized for a shorter disorder than the one you actually have.
Two studies published this year make that case in two different species. Researchers at Beihang and Peking University used EEG — a cap of sensors that reads electrical activity through the scalp — to scan 36 people with heroin use disorder and found a specific pattern of brain-wave synchronization that predicts how strongly a person craves the drug when shown a cue tied to using, and predicts who responds to brain-stimulation treatment. The pattern held up even after treatment reorganized the surrounding brain activity, according to the study published in NPJ Digital Medicine. Craving, in other words, isn’t a mood or a failure of resolve. It’s a measurable brain state.
Separately, a rat study published in Neuropsychopharmacology found that cues once linked to heroin could still trigger relapse-seeking behavior more than a year after the animals’ last exposure to the drug, with no sign the pull was fading. Rats don’t have a willpower narrative to fail at. They just kept responding to the cue, on schedule, over a year later.
If you’re two or three years out and a specific stairwell, a phone number, or a particular hour of the night still puts a hook in your chest, that isn’t a warning sign that you’re about to fail. It’s what that EEG pattern looks like when the light’s still on somewhere in your brain. The actual failure is a system that treats a craving spike in month thirty as a new problem instead of the same disorder, still running quietly underneath a sobriety date.
There’s a genuinely useful finding in the same window of research: a study in Applied Psychology: Health and Well-Being found that a single session of aerobic or resistance exercise measurably reduced craving intensity and the pull of drug-related cues in people with heroin use disorder, while improving the impulse control that makes those cues easier to sit with. Not a cure. A lever you can pull the same day, that doesn’t expire when an insurance authorization does.
The craving isn’t the relapse. Treating it like the relapse — like evidence you failed, instead of evidence your brain is still healing on its own long timeline — is what actually puts people’s sobriety at risk.
Sources Cited
- 01.A
- 02.A
- 03.APersistent vulnerability to heroin relapse after more than one year of abstinence in ratsNeuropsychopharmacology
- 04.AAcute effects of aerobic and resistance exercise on craving and cognitive function in individuals with heroin use disorderApplied Psychology: Health and Well-Being
Filed Under
psychologytreatmentHeroin
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Psilocybin Lowered Inflammation Markers in Parkinson's Patients. Don't Let Anyone Tell You What That Proves.
A JAMA Psychiatry study reports lower inflammation markers in people with Parkinson's disease after psilocybin. It was small and had no control group. What it can and cannot tell clinicians.
Science & MedicineDoubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?
A meta-analysis of 41 THC experiments finds that doubling the dose from 5 to 10 mg raised the self-reported high by about 15 percent and left anxiety unchanged. What it means for people who use, and for providers.
Science & MedicineTwo Postdocs Are Telling the DEA That Schedule I Is Not a Place to Park Uncertainty
Students for Sensible Drug Policy, two early-career scientists and MindState Design Labs asked the DEA for a hearing on placing five tryptamines in Schedule I. What the proposal covers, what it doesn't, and who it could hit first.